Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights Mar 9, 2017
Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings Mar 6, 2017
Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study Mar 1, 2017
Aurinia’s New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference Feb 10, 2017
Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer Feb 6, 2017
